PS
CRSP icon

Principal Securities’s CRISPR Therapeutics CRSP Stock Holding History

Principal Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-241
Closed -$15.6K – 1783
2025
Q3 		$15.6K Buy
241
+182
+308% +$10.4K ﹤0.01% 2527
2025
Q2 		$2.87K Sell
59
-12
-17% -$464 ﹤0.01% 3032
2025
Q1 		$2.79K Hold
71
– – ﹤0.01% 2948
2024
Q4 		$2.79K Sell
71
-576
-89% -$27.2K ﹤0.01% 2943
2024
Q3 		$30.4K Buy
647
+7
+1% +$355 ﹤0.01% 1916
2024
Q2 		$34.6K Sell
640
-706
-52% -$40.8K ﹤0.01% 1793
2024
Q1 		$91.7K Buy
1,346
+695
+107% +$49.8K ﹤0.01% 1309
2023
Q4 		$40.8K Buy
+651
New +$36K ﹤0.01% 1579

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return